Showing results (191-200 of 757) with videos related to

Sort By:
Pageof 76
International Urology and Nephrology|September 15, 2014
Upper and lower urinary tract infections can be detected early but not be discriminated by urinary NGAL in adultsAnja Urbschat, Nicholas Obermüller, Patrick Paulus, et al.
Cells|November 2, 2019
Isolation, Characterization, Differentiation and Immunomodulatory Capacity of Mesenchymal Stromal/Stem Cells from Human Perirenal Adipose TissuePatrick C Baer, Benjamin Koch, Elena Hickmann, et al.
European Journal of Medical Genetics|June 14, 2019
Why systematic literature reviews in Fabry disease should include all published evidencePerry M Elliott, Dominique P Germain, Max J Hilz, et al.
Clinical Chemistry|October 15, 2016
High Glycated Albumin and Mortality in Persons with Diabetes Mellitus on HemodialysisChristina W Chen, Christiane Drechsler, Pirianthini Suntharalingam, et al.
Cardiovascular Diabetology|August 4, 2022
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetesMelanie J Davies, Heinz Drexel, François R Jornayvaz, et al.
Nature Clinical Practice. Nephrology|April 24, 2008
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adultsAlberto Ortiz, João P Oliveira, Christoph Wanner, et al.
American Journal of Nephrology|January 11, 2018
Long-Term Survivor Characteristics in Hemodialysis Patients with Type 2 DiabetesSusanne Triebswetter, Lena J Gutjahr-Lengsfeld, Kay-Renke Schmidt, et al.
Cardiovascular Ultrasound|September 17, 2020
Quantification of left ventricular mass by echocardiography compared to cardiac magnet resonance imaging in hemodialysis patientsSören Jendrik Grebe, Uwe Malzahn, Julian Donhauser, et al.
Kidney & Blood Pressure Research|December 2, 2006
Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertensionThomas Quaschning, Berthold Hocher, Sabine Ruhl, et al.
Frontiers in Pharmacology|February 11, 2022
Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk MarkersSok Cin Tye, Sieta T de Vries, Christoph Wanner, et al.
Pageof 76